Xarelto and Myelosuppression - a phase IV clinical study of FDA data

Summary:

Myelosuppression is reported as a side effect among people who take Xarelto (rivaroxaban), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Flonase, and have Acute lymphocytic leukemia (all).

The phase IV clinical study analyzes which people have Myelosuppression when taking Xarelto. It is created by eHealthMe based on reports of 210,230 people who have side effects when taking Xarelto from the FDA, and is updated regularly.

What is Xarelto?

Xarelto has active ingredients of rivaroxaban. It is often used in atrial fibrillation/flutter. eHealthMe is studying from 212,377 Xarelto users. Check the latest studies of Xarelto.

What is Myelosuppression?

Myelosuppression (a decrease in the production of blood cells) is found to be associated with 541 drugs and 209 conditions by eHealthMe. Check the latest studies of Myelosuppression.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 22, 2026

210,230 people reported to have side effects when taking Xarelto.
Among them, 19 people (0.01%) have Myelosuppression.

Among these 19 people:

How long have people been on Xarelto when they have Myelosuppression? *

What is the gender of people who have Myelosuppression when taking Xarelto? *

female: 40 %
male: 60 %

What is the age of people who have Myelosuppression when taking Xarelto? *

What are other drugs people take besides Xarelto? *

What are other side effects people have besides Myelosuppression? *

Fever: 7 people, 36.84%
Fatigue (feeling of tiredness): 7 people, 36.84%
Weight Decreased: 7 people, 36.84%
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets): 7 people, 36.84%
Febrile Neutropenia (fever with reduced white blood cells): 6 people, 31.58%
Anaemia (lack of blood): 6 people, 31.58%
Oxygen Saturation Decreased: 6 people, 31.58%
Hypotension (abnormally low blood pressure): 5 people, 26.32%
Hypophagia (reduced food intake): 5 people, 26.32%
Neutrophil Count Decreased (less than normal number of neutrophil a type of blood cell): 5 people, 26.32%

What are the existing conditions these people have? *

Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 4 people, 21.05%
Haemorrhage Subcutaneous (bleeding from skin): 3 people, 15.79%
Insomnia (sleeplessness): 3 people, 15.79%
Systemic Sclerosis (Scleroderma) (an autoimmune or connective tissue disease. it is characterized by thickening of the skin): 3 people, 15.79%
Adult T-Cell Lymphoma/leukaemia (cancer of the immune system's own t-cells): 3 people, 15.79%
Pulmonary Hypertension (increase in blood pressure in the lung artery): 3 people, 15.79%
Blood Uric Acid Increased: 3 people, 15.79%
Ecchymosis (a discoloration of the skin resulting from bleeding underneath): 3 people, 15.79%
Fever: 3 people, 15.79%
Diarrhea: 2 people, 10.53%

* Approximation only. Some reports may have incomplete information.

Do you take Xarelto and have Myelosuppression?

- Check whether Myelosuppression is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Xarelto:

Xarelto (212,377 reports)

Myelosuppression treatments and more:

Myelosuppression (18,470 reports)

Browse all side effects of Xarelto:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Myelosuppression:

Myelosuppression (541 drugs)

Browse all the conditions that are associated with Myelosuppression:

Myelosuppression (209 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on rivaroxaban (the active ingredients of Xarelto) and Xarelto (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.